Skip to main content
$39.13Today:- (-)1Y −25.93%

As of Oct 26, 2026 close

Market cap
$173.57B
P/E (TTM)
9.98
Forward P/E
9.57
Dividend yield
4.56%
52-week range
$35.12$64.16
Volume (live)
-
Avg. volume (3M)
12.83M

Novo Nordisk A/S (NVO) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Novo Nordisk A/S generated DKK 119.10B of operating cash flow and spent DKK 90.11B on capital expenditures. That left free cash flow of DKK 28.99B, down 58.4% from DKK 69.66B a year earlier, or 9.4% of revenue. It returned DKK 51.11B to shareholders through DKK 49.78B in dividends and DKK 1.33B in share buybacks.

Novo Nordisk A/S Cash Flow Statement Analysis

Values in billions DKK

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Novo Nordisk A/S (NVO) - Annual data in billions DKK
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income102.43100.9983.6855.5347.7642.1438.9538.6338.13
Depreciation & Amortization14.678.559.417.366.035.755.663.933.18
Deferred Income Tax0.0026.2020.9913.5411.3210.999.608.9910.55
Stock Based Compensation0.002.292.151.541.040.820.360.410.29
Change in Working Capital3.742.5919.71-5.54-9.06-4.35-3.39-3.37-3.63
Change in Accounts Receivable0.00-14.31-14.21-10.82-12.91-2.82-2.13-2.620.07
Change in Inventory0.00-9.04-7.42-4.77-1.09-0.90-1.31-0.96-1.03
Change in Accounts Payable0.00-0.287.596.723.15-0.64-0.401.15-0.40
Change in Other Working Capital3.740.450.423.34-9.060.010.44-0.93-2.27
Other Operating Activities-1.740.450.426.4624.72-3.40-4.41-3.97-7.35
Net Cash from Operating Activities119.10120.97108.9178.8955.0051.9546.7844.6241.17
Investing Activities
Capital Expenditures-90.11-51.31-38.90-14.75-6.34-22.08-11.23-12.41-8.65
Acquisitions1.00-82.160.00-7.08-18.28-0.39-0.100.371.02
Purchases of Investments-0.72-19.81-13.29-9.74-7.1116.26-0.35-0.25-0.04
Sales/Maturities of Investments10.6724.398.296.651.180.010.150.182.08
Other Investing Activities-29.97-4.15-13.09-2.610.00-16.230.020.03-0.99
Net Cash from Investing Activities-79.16-128.90-43.89-24.92-31.61-22.44-11.51-12.08-6.57
Financing Activities
Debt Repayment24.74-6.34-1.47-2.41-6.694.73-0.740.090.00
Common Stock Repurchased-1.33-20.18-29.92-24.09-19.45-16.86-15.33-15.57-16.85
Dividends Paid-49.78-44.14-31.77-25.30-21.52-20.12-19.41-19.05-18.84
Other Financing Activities-2.040.000.000.000.000.000.000.000.00
Net Cash from Financing Activities-28.418.74-63.16-51.80-25.49-32.24-35.48-34.52-35.69
Summary
Effect of Forex Changes on Cash-0.730.46-0.12-0.240.59-0.46-0.010.04-0.21
Net Change in Cash10.810.811.861.93-1.51-3.19-0.22-1.53-1.30
Cash at Beginning of Period15.6614.3912.6510.7212.2315.4115.6317.1618.46
Cash at End of Period26.4615.6614.3912.6510.7212.2315.4115.6317.16
Free Cash Flow28.9969.6670.0164.1348.6729.8735.5532.2132.52
Supplemental Disclosures
Interest Paid3.420.610.490.270.26----
Income Taxes Paid32.0129.6425.9014.5214.44----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Novo Nordisk A/S Cash Flow

What is Novo Nordisk A/S's free cash flow?

Novo Nordisk A/S generated free cash flow of DKK 28.99B in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of DKK 119.10B minus DKK 90.11B of capital expenditures. That was down 58.4% from DKK 69.66B a year earlier. Free cash flow equaled 9.4% of revenue.

How much does Novo Nordisk A/S spend on capital expenditures?

Novo Nordisk A/S spent DKK 90.11B on capital expenditures in fiscal 2025, compared with DKK 51.31B a year earlier. That equals 75.7% of operating cash flow.

Does Novo Nordisk A/S pay dividends or buy back shares?

Yes. In fiscal 2025 Novo Nordisk A/S returned DKK 49.78B in dividends and DKK 1.33B in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition